Tempus AI to Acquire Personalis in $16.25-Per-Share Deal to Expand MRD Testing and Biopharma Data Capabilities

Tempus AI Inc. (NASDAQ: TEM) announced it will purchase all outstanding shares of Personalis Inc. (PSNL) that it does no...

Read story →

Syndax Pharmaceuticals Holds 2026 Annual Shareholder Meeting Amid Strong Oncology Pipeline and Recent Financial Growth

On June 10, 2026, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) convened its annual meeting of stockholders through a recor...

Read story →